- Home
- TNGX vs KALV Comparison
TNGX vs KALV Comparison
Compare TNGX & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- KALV
- Stock Information
- Founded
- TNGX 2014
- KALV N/A
- Country
- TNGX United States
- KALV United States
- Employees
- TNGX N/A
- KALV N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- KALV Health Care
- Exchange
- TNGX Nasdaq
- KALV Nasdaq
- Market Cap
- TNGX 413.6M
- KALV 421.5M
- IPO Year
- TNGX N/A
- KALV N/A
- Fundamental
- Price
- TNGX $3.13
- KALV $8.86
- Analyst Decision
- TNGX Strong Buy
- KALV Strong Buy
- Analyst Count
- TNGX 8
- KALV 6
- Target Price
- TNGX $13.14
- KALV $26.25
- AVG Volume (30 Days)
- TNGX 1.4M
- KALV 383.3K
- Earning Date
- TNGX 11-06-2024
- KALV 12-05-2024
- Dividend Yield
- TNGX N/A
- KALV N/A
- EPS Growth
- TNGX N/A
- KALV N/A
- EPS
- TNGX N/A
- KALV N/A
- Revenue
- TNGX $43,383,000.00
- KALV N/A
- Revenue This Year
- TNGX $27.73
- KALV N/A
- Revenue Next Year
- TNGX N/A
- KALV N/A
- P/E Ratio
- TNGX N/A
- KALV N/A
- Revenue Growth
- TNGX 15.67
- KALV N/A
- 52 Week Low
- TNGX $2.70
- KALV $7.97
- 52 Week High
- TNGX $13.01
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- TNGX 42.05
- KALV 46.47
- Support Level
- TNGX $2.95
- KALV $8.24
- Resistance Level
- TNGX $3.20
- KALV $8.83
- Average True Range (ATR)
- TNGX 0.27
- KALV 0.53
- MACD
- TNGX 0.08
- KALV 0.06
- Stochastic Oscillator
- TNGX 72.88
- KALV 66.92
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.